A Phase 2 Study to Evaluate Therapies for Inflammatory Bowel Disease
NCT07113522 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 140
Last updated 2026-03-12
Summary
This is a Phase 2, multicenter, platform study in adult participants with IBD (moderately to severely active Crohn's Disease or Ulcerative Colitis). The primary goal of this study is to assess the safety and efficacy of multiple investigational drugs.
Conditions
- Inflammatory Bowel Disease (IBD)
- Ulcerative Colitis (UC)
- Crohn's Disease
Interventions
- DRUG
-
MT-501
MT-501
- DRUG
-
MT-201
MT-201
Sponsors & Collaborators
-
Mirador Therapeutics, Inc.
lead INDUSTRY
Study Design
- Allocation
- NA
- Purpose
- TREATMENT
- Masking
- SINGLE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2025-06-26
- Primary Completion
- 2027-04-30
- Completion
- 2028-02-04
- FDA Drug
- Yes
Countries
- United States
- Canada
- Georgia
- Moldova
- Ukraine
Study Locations
More Related Trials
-
Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders
NCT01540292 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
The Impact of Anti-TNF Exposure on Vedolizumab Effectiveness
NCT02423512 ·Status: COMPLETED
-
Confirmatory Clinical Study in Active Ulcerative Colitis
NCT07296315 ·Status: RECRUITING ·Phase: PHASE2
-
An Open Label Safety and Tolerability Study of AIN457 in Patients With Moderate to Severe Crohn's Disease
NCT01009281 ·Status: TERMINATED ·Phase: PHASE2
-
Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease
NCT02015793 ·Status: COMPLETED ·Phase: PHASE2
-
Induction Study #2 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
NCT03440385 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy
NCT00771667 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of 3 Subcutaneous and 1 Intravenous Dose of E6011 in Subjects With Active Crohn's Disease
NCT02249078 ·Status: WITHDRAWN ·Phase: PHASE1
-
A Study of Icotrokinra in Participants With Moderately to Severely Active Crohn's Disease
NCT07196722 ·Status: RECRUITING ·Phase: PHASE2/PHASE3
-
Triple Combination Therapy in High Risk Crohn's Disease (CD)
NCT02764762 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate Safety, Tolerability and Efficacy of Oral E-B-FAHF-2 in Mild-to-Moderate Crohn's Disease
NCT03992469 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1
-
Study of the Human Anti-TNF Monoclonal Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT00105300 ·Status: COMPLETED ·Phase: PHASE3
-
A Dose-Escalation Study of MDX-1100 in Patients With Active Ulcerative Colitis
NCT00295282 ·Status: COMPLETED ·Phase: PHASE1
-
Medico-economic Evaluation of the Therapeutic Drug Monitoring of Anti-TNF-α Agents in Inflammatory Bowel Diseases
NCT02508012 ·Status: COMPLETED ·Phase: NA
-
Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease
NCT00325078 ·Status: TERMINATED ·Phase: PHASE1/PHASE2
-
Evaluation of the Safety, Tolerability, and Efficacy of MDGN-002 in Adults With Moderate to Severe Active Crohn's Disease or Ulcerative Colitis
NCT03169894 ·Status: TERMINATED ·Phase: PHASE1
-
Safety, Efficacy, and Tolerability Study of ASP3291 in Patients With Active Ulcerative Colitis
NCT01612039 ·Status: COMPLETED ·Phase: PHASE2
-
A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425]
NCT00160524 ·Status: COMPLETED ·Phase: PHASE3
-
A Phase 2 Clinical Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of HRS-7085 Tablets in Patients With Inflammatory Bowel Disease
NCT07229950 ·Status: RECRUITING ·Phase: PHASE2
-
A Study of Vedolizumab and Biologic Agents in Participants With Inflammatory Bowel Disease (IBD)
NCT05596422 ·Status: COMPLETED
-
Long-term Safety Study of Brodalumab in Adults With Crohn's Disease
NCT01199302 ·Status: TERMINATED ·Phase: PHASE2
-
Top Down Versus Step Up Strategies in Crohn's Disease
NCT00554710 ·Status: COMPLETED ·Phase: PHASE4
-
An Efficacy and Safety Study of Anti-TNF Monoclonal Antibody in Patients With Fistulizing Crohn's Disease
NCT00269841 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Efficacy and Safety of Two Drug Regimens in Subjects With Moderate to Severe Crohn's Disease
NCT02065570 ·Status: COMPLETED ·Phase: PHASE3
-
PATHFINDER: Evaluating the Optimal First-Line Treatment Strategy for Moderate-to-Severely Active Ileal-dominant Crohn's Disease
NCT05928039 ·Status: RECRUITING ·Phase: PHASE4